Neuropath Core

神经病核心

• 批准号: 10468283
• 负责人: Ann C. McKee
• 金额: $ 54.98万
• 依托单位: BOSTON UNIVERSITY MEDICAL CAMPUS
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-15 至 2025-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10468283
• 关键词: Alzheimer' s Disease; Alzheimer' s disease pathology; Amyloid; Amyloid beta-Protein; Ancillary Study; Argyrophilic Grain Disease; Attenuated; Autopsy; Behavioral; Biochemical; Biological Assay; Biological Sciences; Boston; Brain; Cell Count; Cessation of life; Clinical; Cognitive; Collection; Communities; Consensus; Data; Dementia; Development; Diagnosis; Diagnostic; Digital Libraries; Disease; Elderly; Enrollment; Epitopes; Evaluation; Family member; Framingham Heart Study; Funding; Future; Genetic Markers; Gliosis; Heterogeneity; Image Analysis; Immunohistochemistry; Lewy Bodies; Magnetic Resonance Imaging; Measurement; Measures; Methods; Monitor; Myelin; Outcome; Participant; Pathologic; Pathology; Pattern; Phenotype; Prevalence; Proteins; Protocols documentation; Qualitative Methods; Recording of previous events; Research Personnel; Slide; Specific qualifier value; Stains; Systems Analysis; Technology; Time; Tissues; Translations; Universities; Vascular Diseases; aging brain; brain tissue; cerebrovascular pathology; clinical diagnosis; cohort; cytokine; demented; density; diagnostic criteria; digital; hippocampal sclerosis; impression; meetings; mild cognitive impairment; neuroinflammation; neuropathology; new technology; novel; operation; programs; tau Proteins

In 1997, the FHS began its brain donation program, and has 568 currently enrolled subjects and 241 who have come to autopsy. As a community-aging brain bank, there is a spectrum of pathologies present, including a significant number of participants that were cognitively intact at the time of death (e.g., CDR 0; 32%), mild cognitively impaired (19%), or demented (48%), including 34.2% with possible or probable AD. This spectrum of disease allows for the study of heterogeneous pathologies on clinical outcomes. Traditional pathological methods used to characterize the distribution of amyloid and tau throughout the brain are semi-quantitative and the diagnosis of AD is dependent on meeting specified thresholds of density and regional involvement. Neuropathological characterization of vascular disease into standard quantification methods is still not uniform and quantification of other pathologies (e.g., Lewy bodies, hippocampal sclerosis, argyrophilic grain disease, etc.) relies on estimation of regional density and a summary impression of overall distribution patterns. Accurate assessment of pathological burden is further complicated by the prevalence of mixed pathologies, which increases with advanced age. Digital technologies offer an exciting opportunity to attenuate the limitations of traditional semi-quantitative methods and provide a level of measurement that is significantly enhanced in its precision and objectivity. The proposed Neuropathology Core proposes to continue neuropathological characterization of FHS participants who come to autopsy integrating longitudinally applied semi-quantification methods with new technologies to allow precise quantification of AD and cerebrovascular pathologies. The aims of the Neuropathology Core are (1) perform state-of-the-art diagnostic neuropathology, (2) develop novel methods for qualitative and quantitative histopathological characterization of the tissue, (3) optimally store and distribute brain tissue, and (4) provide neuropathological data for Project 3 and other ancillary studies by both Framingham Heart Study-Brain Aging Program (FHS-BAP) and external investigators. FHS' neuropathological protocol is already aligned with the Boston University Alzheimer Disease Center (BU ADC) in biospecimen collection, blocking, staining and storage, and will be further aligned with 7 other brain bank cohorts through a newly funded U54 led by Neuropathology Core Leader, Ann McKee and co-Leader Thor Stein. In addition, a digital library of the pathology slides will be generated for each participant and through the Data Core, will be made publicly available.

1997年，FHS开始了大脑捐赠计划，目前有568名受试者和241个 来尸检。作为社区衰老的大脑库，存在各种各样的病理，包括 死亡时认知完整的大量参与者（例如，CDR 0; 32％），轻度 认知受损（19％）或痴呆症（48％），其中34.2％，可能是可能的AD或可能的AD。这个频谱 疾病允许研究临床结果的异质性病理。传统的病理方法 用于表征整个大脑中淀粉样蛋白和tau的分布是半定量的，并且 AD的诊断取决于达到密度和区域参与的指定阈值。 血管疾病中的神经病理学表征为标准定量方法仍然不均匀 和其他病理的定量（例如，刘易体，海马硬化，藻类谷物疾病， 等等）依赖于区域密度的估计以及总体分布模式的摘要印象。准确的 混合病理的流行率更加复杂，这是病理负担的评估 随着年龄的增长而增加。数字技术提供了一个令人兴奋的机会来减轻 传统的半定量方法，并提供了一定程度的测量水平 精度和客观性。拟议的神经病理学核心建议继续神经病理学 对尸检的FHS参与者的表征，集成了纵向应用半定量 使用新技术的方法，可以精确量化AD和脑血管病理。目的 神经病理学核心的核心是（1）执行最新的诊断神经病理学，（2）发展新颖 组织的定性和定量组织病理学表征的方法，（3）最佳存储和 分布脑组织，（4）通过两者为项目3和其他辅助研究提供神经病理学数据 Framingham心脏学习 - 脑老化计划（FHS-BAP）和外部研究人员。 FHS的神经病理学 协议已经与BiosPecimen的波士顿大学阿尔茨海默氏病中心（BU ADC）保持一致 收集，阻塞，染色和存储 由神经病理学核心负责人安·麦基（Ann McKee）和联合领导者托尔·斯坦（Thor Stein）领导的新资助的U54。另外， 病理幻灯片的数字库将为每个参与者生成，并且通过数据核心将是 公开可用。